Next Article in Journal
AR Signaling and the PI3K Pathway in Prostate Cancer
Next Article in Special Issue
HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance
Previous Article in Journal
The Androgen Receptor and VEGF: Mechanisms of Androgen-Regulated Angiogenesis in Prostate Cancer
Previous Article in Special Issue
EGFR Family Members’ Regulation of Autophagy Is at a Crossroads of Cell Survival and Death in Cancer
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessReview
Cancers 2017, 9(4), 33; doi:10.3390/cancers9040033

ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology

1
Research Institute for Applied Bioanalytics and Drug Development, IMC University of Applied Sciences Krems, Krems an der Donau 3500, Austria
2
Institute of Medical and Pharmaceutical Biotechnology, IMC University of Applied Sciences Krems, Krems an der Donau 3500, Austria
*
Author to whom correspondence should be addressed.
Academic Editor: Zhixiang Wang
Received: 23 February 2017 / Revised: 5 April 2017 / Accepted: 6 April 2017 / Published: 12 April 2017
(This article belongs to the Special Issue EGFR Family Signaling in Cancer)
View Full-Text   |   Download PDF [954 KB, uploaded 12 April 2017]   |  

Abstract

ErbB family members represent important biomarkers and drug targets for modern precision therapy. They have gained considerable importance as paradigms for oncoprotein addiction and personalized medicine. This review summarizes the current understanding of ErbB proteins in cell signalling and cancer and describes the molecular rationale of prominent cases of ErbB oncoprotein addiction in different cancer types. In addition, we have highlighted experimental technologies for the development of innovative cancer cell models that accurately predicted clinical ErbB drug efficacies. In the future, such cancer models might facilitate the identification and validation of physiologically relevant novel forms of oncoprotein and non-oncoprotein addiction or synthetic lethality. The identification of genotype-drug response relationships will further advance personalized oncology and improve drug efficacy in the clinic. Finally, we review the most important drugs targeting ErbB family members that are under investigation in clinical trials or that made their way already into clinical routine. Taken together, the functional characterization of ErbB oncoproteins have significantly increased our knowledge on predictive biomarkers, oncoprotein addiction and patient stratification and treatment. View Full-Text
Keywords: ErbB family; oncogene addiction; synthetic lethality; drug discovery; tumour modeling; 3D cell culture; personalized medicine; precision therapy ErbB family; oncogene addiction; synthetic lethality; drug discovery; tumour modeling; 3D cell culture; personalized medicine; precision therapy
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Jacobi, N.; Seeboeck, R.; Hofmann, E.; Eger, A. ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology. Cancers 2017, 9, 33.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top